• Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    • Ohneda K, Hamanaka Y, Kawame H, Fuse N, Nagami F, Suzuki Y, Yamaguchi-Kabata Y, Shimada M, Masamune A, Aoki Y, Ishida T, Yamamoto M.
    • Breast Cancer. 2022 Sep 26. doi: 10.1007/s12282-022-01404-7. Epub ahead of print.
    • Perspectives on Spanish language concordant cancer genetic counseling sessions from the Spanish-speaking population.
    • Jimenez S, Matthews A, Darrah R, Schreiber A, Ricker C, Wolfe Schneider K.
    • J Genet Couns. 2022 Sep 19. doi: 10.1002/jgc4.1628. Epub ahead of print.
    • Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing.
    • Bokkers K, Bleiker EMA, Hoogendam JP, Velthuizen ME, Schreuder HWR, Gerestein CG, Lange JG, Louwers JA, Koudijs MJ, Ausems MGEM, Zweemer RP.
    • Hered Cancer Clin Pract. 2022 Sep 8;20(1):33. doi: 10.1186/s13053-022-00238-w.
    • Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer: a prospective study.
    • Brédart A, Kop JL, Tüchler A, De Pauw A, Cano A, Dick J, Rhiem K, Devilee P, Schmutzler R, Stoppa-Lyonnet D, Dolbeault S.
    • Eur J Hum Genet. 2022 Sep;30(9):1067-1075. doi: 10.1038/s41431-022-01096-9. Epub 2022 Apr 11.
    • Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result.
    • Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R, Del Mastro L, Pronzato P, Varesco L, Bonelli L.
    • J Genet Couns. 2022 Aug 29. doi: 10.1002/jgc4.1630. Epub ahead of print.
    • Psychological characteristics of Japanese patients and their family members receiving genetic counseling: A single-institute exploratory study.
    • Mochiki I, Okugawa Y, Hashizume R, Imai H, Ikejiri M, Ogura T, Nakatani K, Hori H.
    • J Genet Couns. 2022 Aug 25. doi: 10.1002/jgc4.1629. Epub ahead of print.
    • I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.
    • Wilfond BS.
    • J Pediatr. 2022 Aug 16:S0022-3476(22)00728-4. doi: 10.1016/j.jpeds.2022.08.019. Epub ahead of print.
    • Commentary

    Original research:

    Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.

    • Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.
    • Rose E, Hardy MW, Gates R, Stanislaw C, Meisel J, Grinzaid KA.
    • Public Health Genomics. 2022 Aug 9:1-14. doi: 10.1159/000525658. Epub ahead of print.
    • Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical center.
    • Finn CM, McCormick S, Peterson D, Niendorf KB, Rodgers LH.
    • J Genet Couns. 2022 Aug 8. doi: 10.1002/jgc4.1624. Epub ahead of print.
    • A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".
    • Warner NZ, Groarke A.
    • BMC Health Serv Res. 2022 Aug 6;22(1):1007. doi: 10.1186/s12913-022-08372-w.
    • Making BRCA1 genetic test reports easier to understand through user-centered design: A randomized trial.
    • Recchia G, Lawrence ACE, Capacchione L, Freeman ALJ.
    • Genet Med. 2022 Aug;24(8):1684-1696. doi: 10.1016/j.gim.2022.04.016. Epub 2022 May 6.
    • Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review.
    • Gould D, Walker R, Makari-Judson G, Seven M.
    • J Community Genet. 2022 Aug;13(4):371-379. doi: 10.1007/s12687-022-00600-4. Epub 2022 Jul 12.
    • Adapting a Theoretically-Based intervention for underserved clinical populations at increased risk for hereditary Cancer: Lessons learned from the BRCA-Gist experience.
    • Hurtado-de-Mendoza A, Reyna VF, Wolfe CR, Gómez-Trillos S, Sutton AL, Brennan A, Sheppard VB.
    • Prev Med Rep. 2022 Jul 5 [eCollection 2022 Aug];28:101887. doi: 10.1016/j.pmedr.2022.101887.
    • Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.
    • Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA.
    • J Genet Couns. 2022 Jul 28. doi: 10.1002/jgc4.1614. Epub ahead of print.
    • Remote vs in-person BRCA1/2 non-carriers test disclosure: patients' choice during Covid-19 pandemic restriction.
    • Costanzo S, De Summa S, Maurmo L, Digennaro M, Patruno M, Paradiso A.
    • Fam Cancer. 2022 Jul 22. doi: 10.1007/s10689-022-00307-y. Epub ahead of print.
    • Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.
    • Jürgens H, Roht L, Leitsalu L, Nõukas M, Palover M, Nikopensius T, Reigo A, Kals M, Kallak K, Kütner R, Budrikas K, Kuusk S, Valvere V, Laidre P, Toome K, Rekker K, Tooming M, Ülle Murumets, Kahre T, Kruuv-Käo K, Õunap K, Padrik P, Metspalu A, Esko T, Fischer K, Tõnisson N.
    • Front Genet. 2022 Jul 22;13:881100. doi: 10.3389/fgene.2022.881100.
    • Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
    • Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri VN.
    • J Community Genet. 2022 Jul 22. doi: 10.1007/s12687-022-00603-1. Epub ahead of print.
    • A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.
    • Torr B, Jones C, Choi S, Allen S, Kavanaugh G, Hamill M, Garrett A, MacMahon S, Loong L, Reay A, Yuan L, Valganon Petrizan M, Monson K, Perry N, Fallowfield L, Jenkins V, Gold R, Taylor A, Gabe R, Wiggins J, Lucassen A, Manchanda R, Gandhi A, George A, Hubank M, Kemp Z, Evans DG, Bremner S, Turnbull C.
    • J Med Genet. 2022 Jul 22:jmedgenet-2022-108655. doi: 10.1136/jmg-2022-108655. Epub ahead of print.

    Trial registration number: ISRCTN87845055: BRCA-DIRECT- Is digitally delivered information about genetic testing feasible, effective and acceptable to women with breast cancer?. (ISRCTN registry)

    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey.
    • Massarotti C, Buonomo B, Dellino M, Campanella M, De Stefano C, Ferrari A, Anserini P, Lambertini M, Peccatori FA.
    • Cancers (Basel). 2022 Jul 15;14(14):3457. doi: 10.3390/cancers14143457.
    • The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study.
    • Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA.
    • J Pers Med. 2022 Jul 7;12(7):1112. doi: 10.3390/jpm12071112.
    • Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling.
    • Pfledderer CD, Gren LH, Frost CJ, Andrulis IL, Chung WK, Genkinger J, Glendon G, Hopper JL, John EM, Southey M, Terry MB, Daly MB.
    • J Genet Couns. 2022 Jul 6. doi: 10.1002/jgc4.1599. Epub ahead of print.
    • Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.
    • Adolph L, Warias A, Stairs J, Collins-McNeil K, Penney L, Kieser K.
    • BMC Womens Health. 2022 Jun 29;22(1):263. doi: 10.1186/s12905-022-01844-5.
    • Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.
    • Jennings C, Wynn J, Miguel C, Levinson E, Florido ME, White M, Sands CB, Schwartz LA, Daly M, O'Toole K, Buys SS, Glendon G, Hanna D, Andrulis IL, Terry MB, Chung WK, Bradbury A.
    • J Pediatr. 2022 Jun 28:S0022-3476(22)00601-1. doi: 10.1016/j.jpeds.2022.06.027. Epub ahead of print.

    Commentary:

    I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.

    • Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    • Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, Comer-Hagans L, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Balay L, Maga T, Ramamonjiarivelo Z, Balthazar C, Winn R, Watson K, Odoms-Young A, Hoskins KF.
    • BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x.

    Identifier: NCT04082117: Uptake of Genetic Counseling Among African American Women. (ClinicalTrials.gov)

    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 May 2 [eCollection 2022 Jun];41:100989. doi: 10.1016/j.gore.2022.100989.
    • Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
    • Hardy MW, Peshkin BN, Rose E, Ladd MK, Binion S, Tynan M, McBride CM, Grinzaid KA, Schwartz MD.
    • J Community Genet. 2022 Jun;13(3):281-292. doi: 10.1007/s12687-022-00590-3. Epub 2022 Apr 29.
    • Assessing the acceptability, feasibility, and usefulness of a psychosocial screening tool to patients and clinicians in a clinical genetics service in Australia.
    • Monohan K, Purvis R, Sexton A, Kentwell M, Thet M, Stafford L, Forrest L.
    • J Genet Couns. 2022 Jun;31(3):653-662. doi: 10.1002/jgc4.1532. Epub 2021 Nov 17.
    • Transgender patients' perspectives on their cancer genetic counseling experiences.
    • Rolle L, Zayhowski K, Koeller D, Chiluiza D, Carmichael N.
    • J Genet Couns. 2022 Jun;31(3):781-791. doi: 10.1002/jgc4.1544. Epub 2021 Dec 28.
    • Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    • Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R, Stutzin Donoso F, Gold R, Fan A, Downes K, Ford J, Antoniou AC, Kurian AW, Evans DG, Tischkowitz M.
    • Cancers (Basel). 2022 May 31;14(11):2716. doi: 10.3390/cancers14112716.
    • Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer.
    • Sadinsky MB, Power J, Ambrosio E, Palma L, Zeng X, Foulkes WD, Weber E.
    • Curr Oncol. 2022 May 15;29(5):3565-3575. doi: 10.3390/curroncol29050288.
    • Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis.
    • Kritzik R, Usoro E, Peshkin BN, Isaacs C, Valdimarsdottir HB, Willey S, O'Neill S, DeMarco T, Nusbaum R, Jandorf L, Kelleher S, Schwartz MD.
    • Psychooncology. 2022 May;31(5):788-797. doi: 10.1002/pon.5863. Epub 2021 Dec 18.
    • Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews.
    • Gaba F, Oxley S, Liu X, Yang X, Chandrasekaran D, Kalsi J, Antoniou A, Side L, Sanderson S, Waller J, Ahmed M, Wallace A, Wallis Y, Menon U, Jacobs I, Legood R, Marks D, Manchanda R.
    • Diagnostics (Basel). 2022 Apr 19;12(5):1028. doi: 10.3390/diagnostics12051028.
    • Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
    • McCuaig JM, Ferguson SE, Vicus D, Ott K, Stockley TL, Kim RH, Metcalfe KA.
    • Hered Cancer Clin Pract. 2022 Apr 13;20(1):15. doi: 10.1186/s13053-022-00221-5.
    • Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.
    • Ongaro G, Petrocchi S, Calvello M, Bonanni B, Feroce I, Pravettoni G.
    • Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203.
    • Large-scale group genetic counseling: Evaluation of a novel service delivery model in a Canadian hereditary cancer clinic.
    • Lohn Z, Fok A, Richardson M, Derocher H, Mung SW, Nuk J, Yuson J, Jevon M, A Schrader K, Sun S.
    • J Genet Couns. 2022 Apr;31(2):459-469. doi: 10.1002/jgc4.1512. Epub 2021 Oct 1.
    • Japanese women's reasons for accompaniment status to hereditary breast and ovarian cancer-focused genetic counseling.
    • Matsukawa M, Torishima M, Satoh C, Honda S, Kosugi S.
    • J Genet Couns. 2022 Apr;31(2):497-509. doi: 10.1002/jgc4.1519. Epub 2021 Oct 18.
    • Assessing the relationship between patient preferences for recontact after BRCA1 or BRCA2 genetic testing and their monitoring coping style in a Norwegian sample.
    • Dahle Ommundsen RM, Strømsvik N, Hamang A.
    • J Genet Couns. 2022 Apr;31(2):554-564. doi: 10.1002/jgc4.1526. Epub 2021 Oct 30.
    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger TE, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC, On Behalf Of The Cascade Consortium.
    • Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636.
    • Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    • Weinmann S, Phillips S, Sweet K, Cosgrove CM, Senter L.
    • Gynecol Oncol. 2022 Mar;164(3):615-621. doi: 10.1016/j.ygyno.2021.12.027. Epub 2022 Jan 5.
    • "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.
    • Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM.
    • Hered Cancer Clin Pract. 2022 Feb 5;20(1):6. doi: 10.1186/s13053-022-00212-6.
    • Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study.
    • Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R.
    • J Community Genet. 2022 Feb;13(1):59-73. doi: 10.1007/s12687-021-00559-8. Epub 2021 Nov 2.
    • Heterogeneity in how women value risk-stratified breast screening.
    • Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJzerman MJ, Trainer AH.
    • Genet Med. 2022 Jan;24(1):146-156. doi: 10.1016/j.gim.2021.09.002. Epub 2021 Nov 30.
    • Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study.
    • Forbes Shepherd R, Forrest LE, Tutty E, Pearce A, Devereux L, James PA, Campbell IG, Trainer A, Young MA.
    • Genet Test Mol Biomarkers. 2021 Dec;25(12):741-748. doi: 10.1089/gtmb.2021.0115.
    • Understanding patients' views and willingness toward the use of telehealth in a cancer genetics service in Asia.
    • Sim J, Shaw T, Li ST, Courtney E, Yuen J, Chiang J, Nazir M, Tan R, Ngeow J.
    • J Genet Couns. 2021 Dec;30(6):1658-1670. doi: 10.1002/jgc4.1432. Epub 2021 May 1.
    • The role of psychosocial factors in Black women's self-efficacy in receiving genetic counseling and testing.
    • Ding H, Sutton AL, Hurtado-de-Mendoza A, Sheppard VB.
    • J Genet Couns. 2021 Dec;30(6):1719-1726. doi: 10.1002/jgc4.1439. Epub 2021 Jun 4.
    • Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    • Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS.
    • Cancer Res Treat. 2021 Nov 17. doi: 10.4143/crt.2021.978. Epub ahead of print.
    • What is empathy? Oncology patient perspectives on empathic clinician behaviors.
    • Sanders JJ, Dubey M, Hall JA, Catzen HZ, Blanch-Hartigan D, Schwartz R.
    • Cancer. 2021 Nov 15;127(22):4258-4265. doi: 10.1002/cncr.33834. Epub 2021 Aug 5.
    • Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes.
    • Binion S, Sorgen LJ, Peshkin BN, Valdimarsdottir H, Isaacs C, Nusbaum R, Graves KD, DeMarco T, Wood M, McKinnon W, Garber J, McCormick S, Ladd MK, Schwartz MD.
    • J Telemed Telecare. 2021 Nov 15:1357633X211052220. doi: 10.1177/1357633X211052220. Epub ahead of print.
    • Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    • Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.
    • Genet Med. 2021 Nov;23(11):2105-2113. doi: 10.1038/s41436-021-01262-2. Epub 2021 Jul 13.
    • Experience and Perceptions of a Family Health History Risk Assessment Tool among Multi-Ethnic Asian Breast Cancer Patients.
    • Yoon S, Goh H, Fung SM, Tang S, Matchar D, Ginsburg GS, Orlando LA, Ngeow J, Wu RR.
    • J Pers Med. 2021 Oct 19;11(10):1046. doi: 10.3390/jpm11101046.
    • Telehealth genetic services during the COVID-19 Pandemic: Implementation and patient experiences across multiple specialties in Nebraska.
    • Rezich BMZ, Malone JA, Reiser G, Zimmerman HH, Blase TL, Fishler KP.
    • J Genet Couns. 2021 Oct;30(5):1233-1243. doi: 10.1002/jgc4.1507. Epub 2021 Oct 7.
    • Alternative Genetic Counseling Approach Leads to Higher Patient Satisfaction, Study Suggests.
    • Curtin C.
    • GenomeWeb. Research & Discovery. 2021 Sep 27.
    • Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    • Augustinsson A, Nilsson MP, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Breast Cancer Res Treat. 2021 Sep 16:1–9. doi: 10.1007/s10549-021-06351-z. Epub ahead of print.
    • Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer.
    • Villafane-Bernier C, Lapointe J, Raîche C, Lauzier S, Chiquette J, Bouchard K, Pelletier S, Omeranovic A, Rhéaume J, Brousseau C, Hébert J, Dorval M, Nabi H.
    • Healthcare (Basel). 2021 Sep 2;9(9):1145. doi: 10.3390/healthcare9091145.
    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D Jr, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021 Sep 1;5:PO.21.00238. doi: 10.1200/PO.21.00238.

    Research news: Men Give Thumbs Up to Video on Genetic Testing in Prostate Cancer. (Medscape Oncology)

    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper.
    • Cousens NE, Tiller J, Meiser B, Barlow-Stewart K, Rowley S, Ko YA, Mahale S, Campbell IG, Kaur R, Bankier A, Burnett L, Jacobs C, James PA, Trainer A, Neil S, Delatycki MB, Andrews L.
    • BMJ Open. 2021 Jun 25;11(6):e041186. doi: 10.1136/bmjopen-2020-041186.
    • Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial.
    • Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M.
    • Genes (Basel). 2021 Jun 20;12(6):941. doi: 10.3390/genes12060941.
    • Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    • Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ.
    • NPJ Breast Cancer. 2021 Jun 17;7(1):78. doi: 10.1038/s41523-021-00288-8.
    • Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas.
    • Almeida R, Lopez-Macha A, Dugatkin T, Joseph G, Duron Y, Hurtado de Mendoza A, D Graves K, Fejerman L.
    • Health Educ Res. 2021 Jun 11:cyab011. doi: 10.1093/her/cyab011. Epub ahead of print.
    • The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
    • Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
    • J Genet Couns. 2021 Jun;30(3):656-664. doi: 10.1002/jgc4.1345. Epub 2020 Nov 3.
    • State of recent literature on communication about cancer genetic testing among Latinx populations.
    • Chavez-Yenter D, Chou WS, Kaphingst KA.
    • J Genet Couns. 2021 Jun;30(3):911-918. doi: 10.1002/jgc4.1351. Epub 2020 Nov 3.
    • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
    • Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau MÈ, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H.
    • Cancers (Basel). 2021 May 31;13(11):2729. doi: 10.3390/cancers13112729.
    • Genetic Testing Challenges in Oncology: Immigrant Mislabeled as BRCA-Positive, Regrets Ovary Removal.
    • Ray T.
    • Precision Oncology News. Diagnostics. Molecular Diagnostics. 2021 May 28.
    • Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    • Warias A, Ferguson M, Chamberlain E, Currie L, Snow N, Matheson K, Penney LS, Kieser K.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1416. Epub ahead of print.
    • Preferences for and acceptability of receiving pharmacogenomic results by mail: A focus group study with a primarily African-American cohort.
    • Chan PA, Lewis KL, Biesecker BB, Erby LH, Fasaye GA, Epps S, Biesecker LG, Turbitt E.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1424. Epub ahead of print.
    • The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.
    • Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.
    • Cancers (Basel). 2021 Apr 15;13(8):1894. doi: 10.3390/cancers13081894.
    • A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.
    • McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH.
    • Curr Oncol. 2021 Apr 8;28(2):1459-1471. doi: 10.3390/curroncol28020138.
    • Videoconferencing to deliver genetics services: a systematic review of telegenetics in light of the COVID-19 pandemic.
    • Brown EG, Watts I, Beales ER, Maudhoo A, Hayward J, Sheridan E, Rafi I.
    • Genet Med. 2021 Apr 6. doi: 10.1038/s41436-021-01149-2. Epub ahead of print.
    • Patients' and professionals' perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic.
    • López-Fernández A, Villacampa G, Grau E, Salinas M, Darder E, Carrasco E, Torres-Esquius S, Iglesias S, Solanes A, Gadea N, Velasco A, Urgell G, Torres M, Tuset N, Brunet J, Corbella S, Balmaña J.
    • Genet Med. 2021 Apr 6. doi: 10.1038/s41436-021-01157-2. Epub ahead of print.
    • Psychosocial Interventions for Women with a BRCA1 or BRCA2 Mutation: A Scoping Review.
    • Boghosian T, McCuaig JM, Carlsson L, Metcalfe KA.
    • Cancers (Basel). 2021 Mar 24;13(7):1486. doi: 10.3390/cancers13071486.
    • Clinical implementation of an oncology-specific family health history risk assessment tool.
    • Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J.
    • Hered Cancer Clin Pract. 2021 Mar 20;19(1):20. doi: 10.1186/s13053-021-00177-y.
    • Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.
    • Pozzar RA, Hong F, Xiong N, Stopfer JE, Nayak MM, Underhill-Blazey M.
    • Fam Cancer. 2021 Mar 10. doi: 10.1007/s10689-021-00240-6. Epub ahead of print.
    • Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
    • Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, Aliyas I, Lim MCK, Suberamaniam A, Mat Adenan NA, Ahmad ZA, Ho GF, Abdul Malik R, Subramaniam S, Khoo BP, Raja A, Chin YS, Sim WW, Teh BH, Kho SK, Ong ESE, Voon PJ, Ismail G, Lee CL, Abdullah BZ, Loo KS, Lim CS, Lee SJ, Lim KJL, Shafiee MN, Ismail F, Latiff ZA, Ismail MP, Mohamed Jamli MF, Kumarasamy S, Leong KW, Low J, Md Yusof M, Ahmad Mustafa AM, Mat Ali NH, Makanjang M, Tayib S, Cheah N, Lim BK, Fong CK, Foo YC, Mellor Abdullah M, Tan TS, Chow DSY, Ho KF, Raman R, Radzi A, Deniel A, Teoh DCY, Ang SF, Joseph JK, Ng PHO, Tho LM, Ahmad AR, Muin I, Bleiker E, George A, Thong MK, Woo YL, Teo SH.
    • J Med Genet. 2021 Feb 1:jmedgenet-2020-107416. doi: 10.1136/jmedgenet-2020-107416. Epub ahead of print.
    • Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.
    • Velthuizen ME, van der Luijt RB, de Vries BJ, Koudijs MJ, Bleiker EMA, Ausems MGEM.
    • Hered Cancer Clin Pract. 2021 Jan 19;19(1):9. doi: 10.1186/s13053-021-00166-1.
    • Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
    • Koptiuch C, Espinel WF, Kohlmann WK, Zhao J, Kaphingst KA.
    • JCO Precis Oncol. 2021 Jan 19;5:PO.20.00199. doi: 10.1200/PO.20.00199.
    • An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia.
    • Yuen J, Fung SM, Sia CL, Venkatramani M, Shaw T, Courtney E, Li ST, Chiang J, Tan VK, Tan BK, Ngeow J.
    • Hered Cancer Clin Pract. 2020 Oct 23;18:22. doi: 10.1186/s13053-020-00154-x.
    • Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.
    • McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ.
    • J Racial Ethn Health Disparities. 2020 Oct 6. doi: 10.1007/s40615-020-00878-5. Epub ahead of print.
    • Impact of Numeracy Preferences on Information Needs for Genome Sequencing Results.
    • Albrechtsen RD, Goodman MS, Bathar J, Kaphingst KA.
    • Patient Educ Couns. 2020 Sep 25:S0738-3991(20)305309. doi: 10.1016/j.pec.2020.09.032. Epub ahead of print.
    • Informing models of cancer genetic care in the era of multigene panel testing with patient-led recommendations.
    • Underhill-Blazey M, Blonquist T, Chittenden A, Pozzar R, Nayak M, Lansang K, Hong F, Garber J, Stopfer JE.
    • J Genet Couns. 2020 Aug 26. doi: 10.1002/jgc4.1317. Epub ahead of print.
    • Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing.
    • Shilling V, Catt S, Jenkins V, Fallowfield L.
    • Breast Cancer Res Treat. 2020 Aug 18. doi: 10.1007/s10549-020-05871-4. Epub ahead of print.
    • Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    • Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, Karlea A, Kobelka C, Lee J, Littell RD, Roh J, Vay A, Kushi LH.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33662-3. doi: 10.1016/j.ygyno.2020.07.027. Epub ahead of print.
    • Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial.
    • Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, Matasar M, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES.
    • J Community Genet. 2020 Jul 16. doi: 10.1007/s12687-020-00478-0. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • How to improve the identification of patients with cancer eligible for genetic counselling?
    • Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E.
    • Eur J Cancer Care (Engl). 2020 Jun 8:e13276. doi: 10.1111/ecc.13276. Epub ahead of print.
    • "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    • Gill G, Beard C, Storey K, Taylor S, Sexton A.
    • Psychooncology. 2020 Jun 4. doi: 10.1002/pon.5436. Epub ahead of print.
    • Women's responses and understanding of polygenic breast cancer risk information.
    • Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerny S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, James PA, Young MA.
    • Fam Cancer. 2020 May 20. doi: 10.1007/s10689-020-00185-2. Epub ahead of print.
    • What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
    • Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S.
    • Prostate. 2020 Apr;80(5):441-450. doi: 10.1002/pros.23959. Epub 2020 Feb 6.
    • Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test.
    • Hamilton JG, Genoff Garzon M, Shah IH, Cadet K, Shuk E, Westerman JS, Hay JL, Offit K, Robson ME.
    • Public Health Genomics. 2020 Mar 19:1-14. doi: 10.1159/000505854. [Epub ahead of print]
    • Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
    • Eden KB, Ivlev I, Bensching KL, Franta G, Hersh AR, Case J, Fu R, Nelson HD.
    • J Womens Health (Larchmt). 2020 Mar 10. doi: 10.1089/jwh.2019.8143. [Epub ahead of print]
    • Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction.
    • Hynes J, MacMillan A, Fernandez S, Jacob K, Carter S, Predham S, Etchegary H, Dawson L.
    • Hered Cancer Clin Pract. 2020 Feb 19;18:3. doi: 10.1186/s13053-020-0136-2. eCollection 2020.
    • Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats.
    • Henneman L, van Asperen CJ, Oosterwijk JC, Menko FH, Claassen L, Timmermans DR.
    • Patient Prefer Adherence. 2020 Feb 19;14:333-342. doi: 10.2147/PPA.S232941. eCollection 2020.
    • The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.
    • Therond C, Lanceley A, Gibbon S, Rahman B.
    • Anthropol Med. 2020 Feb 3:1-16. doi: 10.1080/13648470.2019.1663784. [Epub ahead of print]
    • Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System.
    • Richardson M, Min HJ, Hong Q, Compton K, Mung SW, Lohn Z, Nuk J, McCullum M, Portigal-Todd C, Karsan A, Regier D, Brotto LA, Sun S, Schrader KA.
    • Cancers (Basel). 2020 Feb 3;12(2). pii: E338. doi: 10.3390/cancers12020338.
    • Evaluating empowerment in genetic counseling using patient-reported outcomes.
    • Yuen J, Lee SY, Courtney E, Lim J, Soh H, Li ST, Chen Y, McAllister M, Fenwick EK, Ngeow J.
    • Clin Genet. 2020 Feb;97(2):246-256. doi: 10.1111/cge.13646. Epub 2019 Oct 23.
    • Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
    • Waltz M, Prince AER, O'Daniel JM, Foreman AKM, Powell BC, Berg JS.
    • J Genet Couns. 2020 Jan 22. doi: 10.1002/jgc4.1219. [Epub ahead of print]
    • Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    • Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires , Christos P, Anderson S, Mukherjee S, Jordan B, Blank , Caputo TA, Sharaf , Offit K, Holcomb K, Lipkin S.
    • J Clin Oncol. 2020 Jan 10:JCO1902005. doi: 10.1200/JCO.19.02005. [Epub ahead of print]
    • Latinas' knowledge of and experiences with genetic cancer risk assessment: Barriers and facilitators.
    • Gómez-Trillos S, Sheppard VB, Graves KD, Song M, Anderson L, Ostrove N, Lopez K, Campos C, Gonzalez N, Hurtado-de-Mendoza A.
    • J Genet Couns. 2019 Dec 27. doi: 10.1002/jgc4.1201. [Epub ahead of print]
    • Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences.
    • Clift KE, Macklin SK, Hines SL.
    • Hered Cancer Clin Pract. 2019 Dec 16;17:32. doi: 10.1186/s13053-019-0132-6. eCollection 2019.
    • Black Women's Confidence in the Genetic Information Nondiscrimination Act.
    • Sutton AL, Henderson A, Hurtado-de-Mendoza A, Tanner E, Khan M, Quillin J, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Dec 14;16(24). pii: E5112. doi: 10.3390/ijerph16245112.
    • Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing.
    • Cheng X, Gu Z, Sun X, Zhuang Z.
    • Transl Cancer Res. 2019 Dec;8(8):2893-2905. doi: 10.21037/tcr.2019.11.43.
    • Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.
    • McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.
    • Int J Gynecol Cancer. 2019 Nov 19. pii: ijgc-2019-000630. doi: 10.1136/ijgc-2019-000630. [Epub ahead of print]
    • Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.
    • Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A.
    • Hered Cancer Clin Pract. 2019 Oct 23;17:30. doi: 10.1186/s13053-019-0129-1.
    • Research participants' experiences with return of genetic research results and preferences for web-based alternatives.
    • Gaieski JB, Patrick-Miller L, Egleston BL, Maxwell KN, Walser S, DiGiovanni L, Brower J, Fetzer D, Ganzak A, McKenna D, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM, Bradbury AR.
    • Mol Genet Genomic Med. 2019 Aug 3:e898. doi: 10.1002/mgg3.898. [Epub ahead of print]
    • MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    • Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, Lu KH.
    • BMC Cancer. 2019 Jul 2;19(1):648. doi: 10.1186/s12885-019-5868-x.
    • The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
    • Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, Tsuda H, Watanabe Y, Yoshihara K, Sugiyama T.
    • Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384.
    • Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing.
    • Van de Beek I, Smets EMA, Legdeur MA, de Hullu JA, Lok CAR, Buist MR, Mourits MJE, Kets CM, van der Kolk LE, Oosterwijk JC, Aalfs CM.
    • J Community Genet. 2019 Jun 5. doi: 10.1007/s12687-019-00427-6. [Epub ahead of print]
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • A qualitative study on decision-making about BRCA1/2 testing in Italian women.
    • Battistuzzi L, Franiuk M, Kasparian N, Rania N, Migliorini L, Varesco L.
    • Eur J Cancer Care (Engl). 2019 May 5:e13083. doi: 10.1111/ecc.13083. [Epub ahead of print]
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • A narrative overview of the patients' outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling.
    • Esteban I, Lopez-Fernandez A, Balmaña J.
    • Eur J Med Genet. 2019 May;62(5):342-349. doi: 10.1016/j.ejmg.2018.11.027. Epub 2018 Nov 23.
    • Review
    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Expectations versus reality: The impact of men's expectancy violations in conversations with healthcare providers about BRCA-related cancer risks.
    • Dean M, Rauscher E, Gomez E, Fischer C.
    • Patient Educ Couns. 2019 Apr 6. pii: S0738-3991(19)30135-1. doi: 10.1016/j.pec.2019.04.010. [Epub ahead of print]
    • Communication about genetic testing with breast and ovarian cancer patients: a scoping review.
    • Jacobs C, Patch C, Michie S.
    • Eur J Hum Genet. 2019 Apr;27(4):511-524. doi: 10.1038/s41431-018-0310-4. Epub 2018 Dec 20.
    • Uncertainty related to multigene panel testing for cancer: a qualitative study on counsellors' and counselees' views.
    • Medendorp NM, Hillen MA, Murugesu L, Aalfs CM, Stiggelbout AM, Smets EMA.
    • J Community Genet. 2019 Apr;10(2):303-312. doi: 10.1007/s12687-018-0393-1. Epub 2018 Nov 14.
    • Evaluation of the template letter regarding the disclosure of genetic information within the family in France.
    • Zordan C, Monteil L, Haquet E, Cordier C, Toussaint E, Roche P, Dorian V, Maillard A, Lhomme E, Richert L, Pasquier L, Akloul L, Taris N, Lacombe D.
    • J Community Genet. 2019 Mar 27. doi: 10.1007/s12687-019-00418-7. [Epub ahead of print]
    • Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.
    • Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR.
    • Clin Genet. 2019 Feb;95(2):293-301. doi: 10.1111/cge.13474. Epub 2018 Dec 7.
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer.
    • McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA.
    • Cancers (Basel). 2018 Nov 13;10(11). pii: E435. doi: 10.3390/cancers10110435.
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives.
    • Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P.
    • Mol Genet Genomic Med. 2018 Nov;6(6):957-965. doi: 10.1002/mgg3.464. Epub 2018 Oct 11.
    • Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
    • DeFrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, Alico L, Adkins RT.
    • Obstet Gynecol. 2018 Nov;132(5):1121-1129. doi: 10.1097/AOG.0000000000002916.
    • Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.
    • Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS.
    • J Natl Cancer Inst. 2018 Sep 1;110(9):985-993. doi: 10.1093/jnci/djy015.
    • Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
    • Puski A, Hovick S, Senter L, Toland AE4.
    • J Genet Couns. 2018 Sep;27(5):1291-1301. doi: 10.1007/s10897-018-0254-4. Epub 2018 Mar 29.
    • Maternal perceptions of BRCA genetic counseling communication processes about disclosing cancer risk information to children and adult relatives.
    • Hamilton JG, Peshkin BN, Mays D, DeMarco TA, Patenaude AF, Tercyak KP.
    • Psychooncology. 2018 Jul;27(7):1825-1832. doi: 10.1002/pon.4733. Epub 2018 May 22.
    • Timing and Mode of Breast Care Nurse Consultation From the Patient's Perspective.
    • Brown J, Refeld G, Cooper A.
    • Oncol Nurs Forum. 2018 May 1;45(3):389-398. doi: 10.1188/18.ONF.389-398.
    • Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    • Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.
    • J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.
    • Hereditary Cancer Genetic Testing in Community-Based Obstetrics and Gynecology Settings.
    • Obstet Gynecol. 2018 May;131(5):119s. doi: 10.1097/01.AOG.0000533506.01865.a1.
    • Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    • Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.
    • Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.
    • Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia.
    • D'Andrea E, Lagerberg T, De Vito C, Pitini E, Marzuillo C, Massimi A, Vacchio MR, Grammatico P, Villari P.
    • Eur J Hum Genet. 2018 Apr;26(4):518-526. doi: 10.1038/s41431-017-0083-1. Epub 2018 Jan 26.
    • Impact of a genetic counseling requirement prior to genetic testing.
    • Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI.
    • BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.
    • Patient-Centered Care in Breast Cancer Genetic Clinics.
    • Brédart A, Anota A, Dick J, Kuboth V, Lareyre O, De Pauw A, Cano A, Stoppa-Lyonnet D, Schmutzler R, Dolbeault S, Kop JL.
    • Int J Environ Res Public Health. 2018 Feb 12;15(2). pii: E319. doi: 10.3390/ijerph15020319.
    • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    • Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N.
    • Breast Cancer Res Treat. 2018 Feb;168(1):117-126. doi: 10.1007/s10549-017-4584-y. Epub 2017 Nov 21.
    • Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
    • Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG.
    • J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.
    • Examination of the Patient-Focused Impact of Cancer Telegenetics Among a Rural Population: Comparison with Traditional In-Person Services.
    • Solomons NM, Lamb AE, Lucas FL, McDonald EF, Miesfeldt S.
    • Telemed J E Health. 2018 Feb;24(2):130-138. doi: 10.1089/tmj.2017.0073. Epub 2017 Jul 21.
    • Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review.
    • Fournier DM, Bazzell AF, Dains JE.
    • Oncol Nurs Forum. 2018 Jan 1;45(1):96-105. doi: 10.1188/18.ONF.96-105.
    • Review
    • Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.
    • Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C.
    • Int J Gynecol Cancer. 2018 Jan;28(1):26-33. doi: 10.1097/IGC.0000000000001122.
    • Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    • Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.
    • J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.
    • Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    • Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicuña B, Schwartz MD, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.
    • Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
    • Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M; GTEOC Study Group, Hulbert-Williams NJ.
    • J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
    • Genetic counseling by phone or face-to-face.
    • [No author given]
    • FORCE. XRAYS. 2017 Nov 29.
    • [A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer].
    • Li L, Qiu L, Wu M.
    • Zhonghua Yi Xue Za Zhi. 2017 Nov 21;97(43):3412-3415. doi: 10.3760/cma.j.issn.0376-2491.2017.43.011.
    • English Abstract, [Article in Chinese]
    • Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: consensus across health professionals and service users.
    • Jacobs C, Pichert G, Harris J, Tucker K, Michie S.
    • Psychooncology. 2017 Nov;26(11):1818-1824. doi: 10.1002/pon.4379. Epub 2017 Feb 10.
    • Information Mismatch: Cancer Risk Counseling with Diverse Underserved Patients.
    • Joseph G, Pasick RJ, Schillinger D, Luce J, Guerra C, Cheng JK.
    • J Genet Couns. 2017 Oct;26(5):1090-1104. doi: 10.1007/s10897-017-0089-4. Epub 2017 Mar 13.
    • The power of shared experience: Empowering women to face their cancer risk.
    • Caitlin Lopez
    • NSGC blog, 2017 Aug 30.
    • Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
    • Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, Koka S, Fridman H, Djemal K, Glick I, Zalut T, Segev S, Sklair M, Kaufman B, Lahad A, Raz A, Levy-Lahad E.
    • Genet Med. 2017 Jul;19(7):754-762. doi: 10.1038/gim.2016.182. Epub 2016 Dec 8.
    • High-risk patients with breast cancer may not receive genetic testing.
    • Printz C
    • Cancer. 2017 Jun 1;123(11):1887. doi: 10.1002/cncr.30774.

    Letter, Comment:

    Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer.

    • Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
    • Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R.
    • JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918.
    • Letter, Comment

    Viewpoint:

    Multigene Panel Testing in Oncology Practice: How Should We Respond?

    Research news: High-risk patients with breast cancer may not receive genetic testing. (Cancer)

    Press: Shortage of Genetic Counselors in Face of Growing Need. (Medscape Conference News)

    • Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling.
    • Benusiglio PR, Di Maria M, Dorling L, Jouinot A, Poli A, Villebasse S, Le Mentec M, Claret B, Boinon D, Caron O.
    • Fam Cancer. 2017 Jan;16(1):51-56. doi: 10.1007/s10689-016-9929-x.
    • Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer.
    • Eismann S, Vetter L, Keller M, Bruckner T, Golatta M, Hennings A, Domschke C, Dikow N, Sohn C, Heil J, Schott S.
    • Arch Gynecol Obstet. 2016 Nov;294(5):1011-1018. Epub 2016 Jun 10.
    • Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing.
    • Qiu J, Guan J, Yang X, Wu J, Liu G, Di G, Chen C, Hou Y, Han Q, Shen Z, Shao Z, Hu Z.
    • PLoS One. 2016 Jul 18;11(7):e0158531. doi: 10.1371/journal.pone.0158531. eCollection 2016.
    • Validity of self-reported genetic counseling and genetic testing use among breast cancer survivors.
    • Hamann HA, Tiro JA, Sanders JM, Melhado TV, Funk RK, Carpentier MY, Bartholomew LK, Argenbright KE, Vernon SW.
    • J Cancer Surviv. 2013 Dec;7(4):624-9. doi: 10.1007/s11764-013-0301-y. Epub 2013 Aug 23.
    • Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.
    • Culver J, Brinkerhoff C, Clague J, Yang K, Singh K, Sand S, Weitzel J.
    • Clin Genet. 2013 Nov;84(5):464-472. doi: 10.1111/cge.12097. Epub 2013 Feb 20.
    • Nonverbal communication and conversational contribution in breast cancer genetic counseling: Are counselors' nonverbal communication and conversational contribution associated with counselees' satisfaction, needs fulfillment and state anxiety in breast cancer genetic counseling?
    • Dijkstra H, Albada A, Klöckner Cronauer C, Ausems MG, van Dulmen S.
    • Patient Educ Couns. 2013 Nov;93(2):216-23. doi: 10.1016/j.pec.2013.05.014. Epub 2013 Jun 18.
    • Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
    • Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, Powell MA, Mutch DG, Massad LS, Zighelboim I.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1016-21. doi: 10.1097/IGC.0b013e3182994365.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Timing of referral for ovarian patients

    • Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing.
    • Gleeson M, Meiser B, Barlow-Stewart K, Trainer AH, Tucker K, Watts KJ, Friedlander M, Kasparian N.
    • Oncol Nurs Forum. 2013 May 1;40(3):275-83. doi: 10.1188/13.ONF.40-03AP.
    • Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
    • Vos J, Menko FH, Oosterwijk JC, van Asperen CJ, Stiggelbout AM, Tibben A.
    • Psychooncology. 2013 May;22(5):1167-76. doi: 10.1002/pon.3125. Epub 2012 Jul 9.
    • Theory Development From Studies With Young Women With Breast Cancer Who Are BRCA Mutation Negative.
    • Hamilton R, Kopin S.
    • ANS Adv Nurs Sci. 2013 Apr-Jun;36(2):E41-53. doi: 10.1097/ANS.0b013e3182901ff1.
    • The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    • Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Garcia EG, Tibben A.
    • Psychooncology. 2013 Apr;22(4):902-10. doi: 10.1002/pon.3081. Epub 2012 Jun 27.
    • Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
    • Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.
    • PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

    Comments on NSGC Discussion Forum

    Subject: Current thoughts on 23andme?

    Press: Consumers have few negative reactions to the results of genetic testing for cancer mutations. (EurekAlert!)

    Press: Get ready for the risks of genetic testing. (CNN)

    • Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: A qualitative study of patient preferences.
    • Hurley K, Rubin LR, Werner-Lin A, Sagi M, Kemel Y, Stern R, Phillips A, Cholst I, Kauff N, Offit K.
    • Cancer. 2012 Dec 15;118(24):6270-7. doi: 10.1002/cncr.27695. Epub 2012 Jun 26.
    • Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer.
    • Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, Mitchell G.
    • Support Care Cancer. 2012 Nov;20(11):2949-58. doi: 10.1007/s00520-012-1427-6. Epub 2012 Mar 24.
    • Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs.
    • Espenschied CR, MacDonald DJ, Culver JO, Sand S, Hurley K, Banks KC, Weitzel JN, Blazer KR.
    • J Cancer Educ. 2012 Jun;27(3):467-77. doi: 10.1007/s13187-012-0373-9.
    • A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome.
    • Kardashian A, Fehniger J, Creasman J, Cheung E, Beattie MS.
    • Hered Cancer Clin Pract. 2012 Apr 12;10(1):4. doi: 10.1186/1897-4287-10-4.
    • Patient outcomes associated with group and individual genetic counseling formats.
    • Rothwell E, Kohlmann W, Jasperson K, Gammon A, Wong B, Kinney A.
    • Fam Cancer. 2012 Mar;11(1):97-106. doi: 10.1007/s10689-011-9486-2.
    • Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing.
    • Meiser B, Gleeson M, Watts K, Peate M, Zilliacus E, Barlow-Stewart K, Saunders C, Mitchell G, Kirk J.
    • Oncol Nurs Forum. 2012 Mar;39(2):E101-11. doi: 10.1188/12.ONF.E101-E111.